Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Regorafenib in patients with recurrent high-grade astrocytoma.

Kebir S, Rauschenbach L, Radbruch A, Lazaridis L, Schmidt T, Stoppek AK, Pierscianek D, Stuschke M, Forsting M, Sure U, Keyvani K, Kleinschnitz C, Scheffler B, Glas M.

J Cancer Res Clin Oncol. 2019 Apr;145(4):1037-1042. doi: 10.1007/s00432-019-02868-5. Epub 2019 Feb 28.

PMID:
30820715
2.

Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.

Kobayashi K, Kawakami K, Yokokawa T, Aoyama T, Suzuki K, Wakatsuki T, Suenaga M, Sato H, Sugiyama E, Yamaguchi K, Hama T.

Oncology. 2019;96(4):200-206. doi: 10.1159/000495989. Epub 2019 Feb 14.

PMID:
30763946
3.

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.

Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas S, Perrin C, Delcambre C, Liegl-Atzwanger B, Toulmonde M, Dumont S, Ray-Coquard I, Clisant S, Taieb S, Guillemet C, Rios M, Collard O, Bozec L, Cupissol D, Saada-Bouzid E, Lemaignan C, Eisterer W, Isambert N, Chaigneau L, Cesne AL, Penel N.

Lancet Oncol. 2016 Dec;17(12):1732-1742. doi: 10.1016/S1470-2045(16)30507-1. Epub 2016 Oct 14.

PMID:
27751846
4.

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.

Son MK, Ryu MH, Park JO, Im SA, Kim TY, Lee SJ, Ryoo BY, Park SR, Kang YK.

Cancer Res Treat. 2017 Apr;49(2):350-357. doi: 10.4143/crt.2016.067. Epub 2016 Jul 19.

5.

Anti-angiogenic therapy for high-grade glioma.

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M.

Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218. doi: 10.1002/14651858.CD008218.pub4.

PMID:
30480778
6.

Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.

Karajannis MA, Legault G, Fisher MJ, Milla SS, Cohen KJ, Wisoff JH, Harter DH, Goldberg JD, Hochman T, Merkelson A, Bloom MC, Sievert AJ, Resnick AC, Dhall G, Jones DT, Korshunov A, Pfister SM, Eberhart CG, Zagzag D, Allen JC.

Neuro Oncol. 2014 Oct;16(10):1408-16. doi: 10.1093/neuonc/nou059. Epub 2014 May 6.

7.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
8.

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.

Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D.

J Clin Oncol. 2016 Aug 10;34(23):2728-35. doi: 10.1200/JCO.2015.65.1901. Epub 2016 Jun 20.

9.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators.

Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22.

10.

[Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].

Tanaka A, Sadahiro S, Suzuki T, Okada K, Saito G.

Gan To Kagaku Ryoho. 2014 Oct;41(10):1231-6. Japanese.

PMID:
25335705
11.

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib.

Wong AL, Lim JS, Sinha A, Gopinathan A, Lim R, Tan CS, Soh T, Venkatesh S, Titin C, Sapari NS, Lee SC, Yong WP, Tan DS, Pang B, Wang TT, Zee YK, Soong R, Trnkova Z, Lathia C, Thiery JP, Wilhelm S, Jeffers M, Goh BC.

J Transl Med. 2015 Feb 12;13:57. doi: 10.1186/s12967-015-0405-4.

12.

A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.

Yeh CN, Chen MH, Chen YY, Yang CY, Yen CC, Tzen CY, Chen LT, Chen JS.

Oncotarget. 2017 Jul 4;8(27):44121-44130. doi: 10.18632/oncotarget.17310.

13.

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.

Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, Yamaguchi K, Yamaguchi T.

Oncotarget. 2016 Jun 7;7(23):34811-23. doi: 10.18632/oncotarget.9187.

14.

Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients.

Schvartsman G, Wagner MJ, Amini B, Zobniw CM, Trinh VA, Barbo AG, Lin HY, Wang WL, Conley AP, Ravi V, Araujo DM, Zarzour MA, Benjamin RS, Patel S, Somaiah N.

Sci Rep. 2017 Aug 25;7(1):9519. doi: 10.1038/s41598-017-09132-1.

15.

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.

Eisen T, Joensuu H, Nathan PD, Harper PG, Wojtukiewicz MZ, Nicholson S, Bahl A, Tomczak P, Pyrhonen S, Fife K, Bono P, Boxall J, Wagner A, Jeffers M, Lin T, Quinn DI.

Lancet Oncol. 2012 Oct;13(10):1055-62. doi: 10.1016/S1470-2045(12)70364-9. Epub 2012 Sep 6.

PMID:
22959186
16.

Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.

Ueshima K, Nishida N, Kudo M.

Dig Dis. 2017;35(6):611-617. doi: 10.1159/000480257. Epub 2017 Oct 17.

PMID:
29040994
17.

Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.

Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L.

Eur J Cancer. 2013 Nov;49(16):3412-9. doi: 10.1016/j.ejca.2013.05.028. Epub 2013 Jun 25.

18.

Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.

Chamberlain MC, Johnston S.

J Neurooncol. 2009 Feb;91(3):359-67. doi: 10.1007/s11060-008-9722-2. Epub 2008 Oct 25.

PMID:
18953491
19.

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group.

Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.

PMID:
23177514
20.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators.

Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Erratum in: Lancet. 2017 Jan 7;389(10064):36.

PMID:
27932229

Supplemental Content

Support Center